Health Care [ 5/12 ] | Biotechnology [ 29/74 ]
NASDAQ | Common Stock
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.
It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis.
MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -0.72 Decreased by -500.00% | -0.59 Decreased by -21.46% |
| Nov 12, 24 | -0.56 Decreased by -211.11% | -0.44 Decreased by -27.27% |
| Aug 7, 24 | -0.39 Decreased by -69.57% | -0.28 Decreased by -39.29% |
| May 7, 24 | -0.22 Increased by +4.35% | -0.19 Decreased by -15.79% |
| Feb 29, 24 | -0.12 Increased by +61.29% | -0.23 Increased by +47.83% |
| Nov 14, 23 | -0.18 Increased by +33.33% | -0.23 Increased by +21.74% |
| Aug 10, 23 | -0.23 Increased by +32.35% | -0.27 Increased by +14.81% |
| May 12, 23 | -0.23 Increased by +34.29% | -0.31 Increased by +25.81% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 101.85 K Increased by +416.01% | -120.61 B Decreased by -1.62 M% | Decreased by -118.42 M% Decreased by -314.18 K% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -35.39 M Decreased by -275.45% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -24.27 M Decreased by -139.34% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 19.74 K Increased by +N/A% | -13.67 M Decreased by -11.90% | Decreased by -69.28 K% Decreased by N/A% |
| Dec 31, 23 | 19.74 K Increased by +N/A% | -7.44 M Increased by +54.84% | Decreased by -37.68 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -9.43 M Increased by +36.06% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -10.14 M Increased by +41.78% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -12.22 M Increased by +23.05% | Decreased by N/A% Decreased by N/A% |